Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy

Yu Chen Huang, Chih Ming Weng, Meng Jung Lee, Shu Min Lin, Chun Hua Wang, Han-Pin Kuo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Omalizumab, a recombinant monoclonal anti-IgE antibody, was developed for the treatment of severe allergic asthma. Not all these patients respond to omalizumab. Objective: This study aimed to evaluate whether the proinflammatory cytokine profiles in the severe allergic asthma patients were different between who responded and nonresponded to omalizumab therapy. Methods: A prospective study was conducted to examine type 2 cytokines and epithelium-derived cytokines in the bronchial tissues by immunohistochemistry, Western blot and PCR analysis among patients with severe allergic asthma before and after omalizumab therapy. Results: Fourteen of 23 patients with unstable severe allergic asthma improved their asthma control after 4 months of omalizumab treatment (Responders), while nine failed to improve (Non-Responders). Most of Responders were type 2-high endotype (12/14) with upregulated expression of IL-33, IL-25 and TSLP in their bronchial tissues, while most of Non-Responders were type 2-low endotype (8/9). Repeated bronchoscopic biopsy was done in nine responders after omalizumab treatment and showed a decline in IL-13, IL-33, IL-25 and TSLP expression in the bronchial tissues. Among 14 Responders who continued omalizuamb treatments to a total 12 months, six patients achieved a well control of asthma (ACT ≥ 23), while eight patients required additional treatment for asthma symptoms and had more rhinosinusitis comorbidities and a mixed eosinophilic and neutrophilic inflammation in their bronchial tissues. Conclusion: Most of the severe allergic asthma patients who benefited from omalizumab treatment were IL-33, IL-25 and TSLP aggravated type 2-high endotype. Rhinosinusitis or with a mixed eosinophilic and neutrophilic airway inflammation should be evaluated in patients who partially responded to omalizumab treatment.

Original languageEnglish
Pages (from-to)44-53
Number of pages10
JournalClinical and Experimental Allergy
Volume49
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Asthma
Therapeutics
Cytokines
Inflammation
anti-IgE antibodies
Interleukin-13
Omalizumab
Comorbidity
Epithelium
Western Blotting
Immunohistochemistry
Monoclonal Antibodies
Prospective Studies
Biopsy
Polymerase Chain Reaction
Interleukin-33

Keywords

  • anti-IgE
  • IgE
  • IL-25
  • IL-33
  • severe asthma
  • thymic stromal lymphopoietin
  • type 2 cytokines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy. / Huang, Yu Chen; Weng, Chih Ming; Lee, Meng Jung; Lin, Shu Min; Wang, Chun Hua; Kuo, Han-Pin.

In: Clinical and Experimental Allergy, Vol. 49, No. 1, 01.01.2019, p. 44-53.

Research output: Contribution to journalArticle

Huang, Yu Chen ; Weng, Chih Ming ; Lee, Meng Jung ; Lin, Shu Min ; Wang, Chun Hua ; Kuo, Han-Pin. / Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy. In: Clinical and Experimental Allergy. 2019 ; Vol. 49, No. 1. pp. 44-53.
@article{7f78279bf72e4d7ba0277d29ae9712e2,
title = "Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy",
abstract = "Background: Omalizumab, a recombinant monoclonal anti-IgE antibody, was developed for the treatment of severe allergic asthma. Not all these patients respond to omalizumab. Objective: This study aimed to evaluate whether the proinflammatory cytokine profiles in the severe allergic asthma patients were different between who responded and nonresponded to omalizumab therapy. Methods: A prospective study was conducted to examine type 2 cytokines and epithelium-derived cytokines in the bronchial tissues by immunohistochemistry, Western blot and PCR analysis among patients with severe allergic asthma before and after omalizumab therapy. Results: Fourteen of 23 patients with unstable severe allergic asthma improved their asthma control after 4 months of omalizumab treatment (Responders), while nine failed to improve (Non-Responders). Most of Responders were type 2-high endotype (12/14) with upregulated expression of IL-33, IL-25 and TSLP in their bronchial tissues, while most of Non-Responders were type 2-low endotype (8/9). Repeated bronchoscopic biopsy was done in nine responders after omalizumab treatment and showed a decline in IL-13, IL-33, IL-25 and TSLP expression in the bronchial tissues. Among 14 Responders who continued omalizuamb treatments to a total 12 months, six patients achieved a well control of asthma (ACT ≥ 23), while eight patients required additional treatment for asthma symptoms and had more rhinosinusitis comorbidities and a mixed eosinophilic and neutrophilic inflammation in their bronchial tissues. Conclusion: Most of the severe allergic asthma patients who benefited from omalizumab treatment were IL-33, IL-25 and TSLP aggravated type 2-high endotype. Rhinosinusitis or with a mixed eosinophilic and neutrophilic airway inflammation should be evaluated in patients who partially responded to omalizumab treatment.",
keywords = "anti-IgE, IgE, IL-25, IL-33, severe asthma, thymic stromal lymphopoietin, type 2 cytokines",
author = "Huang, {Yu Chen} and Weng, {Chih Ming} and Lee, {Meng Jung} and Lin, {Shu Min} and Wang, {Chun Hua} and Han-Pin Kuo",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cea.13248",
language = "English",
volume = "49",
pages = "44--53",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy

AU - Huang, Yu Chen

AU - Weng, Chih Ming

AU - Lee, Meng Jung

AU - Lin, Shu Min

AU - Wang, Chun Hua

AU - Kuo, Han-Pin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Omalizumab, a recombinant monoclonal anti-IgE antibody, was developed for the treatment of severe allergic asthma. Not all these patients respond to omalizumab. Objective: This study aimed to evaluate whether the proinflammatory cytokine profiles in the severe allergic asthma patients were different between who responded and nonresponded to omalizumab therapy. Methods: A prospective study was conducted to examine type 2 cytokines and epithelium-derived cytokines in the bronchial tissues by immunohistochemistry, Western blot and PCR analysis among patients with severe allergic asthma before and after omalizumab therapy. Results: Fourteen of 23 patients with unstable severe allergic asthma improved their asthma control after 4 months of omalizumab treatment (Responders), while nine failed to improve (Non-Responders). Most of Responders were type 2-high endotype (12/14) with upregulated expression of IL-33, IL-25 and TSLP in their bronchial tissues, while most of Non-Responders were type 2-low endotype (8/9). Repeated bronchoscopic biopsy was done in nine responders after omalizumab treatment and showed a decline in IL-13, IL-33, IL-25 and TSLP expression in the bronchial tissues. Among 14 Responders who continued omalizuamb treatments to a total 12 months, six patients achieved a well control of asthma (ACT ≥ 23), while eight patients required additional treatment for asthma symptoms and had more rhinosinusitis comorbidities and a mixed eosinophilic and neutrophilic inflammation in their bronchial tissues. Conclusion: Most of the severe allergic asthma patients who benefited from omalizumab treatment were IL-33, IL-25 and TSLP aggravated type 2-high endotype. Rhinosinusitis or with a mixed eosinophilic and neutrophilic airway inflammation should be evaluated in patients who partially responded to omalizumab treatment.

AB - Background: Omalizumab, a recombinant monoclonal anti-IgE antibody, was developed for the treatment of severe allergic asthma. Not all these patients respond to omalizumab. Objective: This study aimed to evaluate whether the proinflammatory cytokine profiles in the severe allergic asthma patients were different between who responded and nonresponded to omalizumab therapy. Methods: A prospective study was conducted to examine type 2 cytokines and epithelium-derived cytokines in the bronchial tissues by immunohistochemistry, Western blot and PCR analysis among patients with severe allergic asthma before and after omalizumab therapy. Results: Fourteen of 23 patients with unstable severe allergic asthma improved their asthma control after 4 months of omalizumab treatment (Responders), while nine failed to improve (Non-Responders). Most of Responders were type 2-high endotype (12/14) with upregulated expression of IL-33, IL-25 and TSLP in their bronchial tissues, while most of Non-Responders were type 2-low endotype (8/9). Repeated bronchoscopic biopsy was done in nine responders after omalizumab treatment and showed a decline in IL-13, IL-33, IL-25 and TSLP expression in the bronchial tissues. Among 14 Responders who continued omalizuamb treatments to a total 12 months, six patients achieved a well control of asthma (ACT ≥ 23), while eight patients required additional treatment for asthma symptoms and had more rhinosinusitis comorbidities and a mixed eosinophilic and neutrophilic inflammation in their bronchial tissues. Conclusion: Most of the severe allergic asthma patients who benefited from omalizumab treatment were IL-33, IL-25 and TSLP aggravated type 2-high endotype. Rhinosinusitis or with a mixed eosinophilic and neutrophilic airway inflammation should be evaluated in patients who partially responded to omalizumab treatment.

KW - anti-IgE

KW - IgE

KW - IL-25

KW - IL-33

KW - severe asthma

KW - thymic stromal lymphopoietin

KW - type 2 cytokines

UR - http://www.scopus.com/inward/record.url?scp=85053037592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053037592&partnerID=8YFLogxK

U2 - 10.1111/cea.13248

DO - 10.1111/cea.13248

M3 - Article

AN - SCOPUS:85053037592

VL - 49

SP - 44

EP - 53

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 1

ER -